Affiliations: [a] Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China | [b] Department of Pathology, Capital Medical University, Beijing, China | [c] Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, China | [d] The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China | [e] Department of Respiratory Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China | [f] General Practice Medicine, The First People’s Hospital of Huzhou, Huzhou, China
Correspondence:
[*]
Corresponding authors: Weilong Zhang and Hongmei Jing, Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing 100191, China. %****␣cbm-36-cbm210042_temp.tex␣Line␣125␣**** E-mail: [email protected]@bjmu.edu.cn.
Note: [1] Xue He, Jing Hu and Changjian Yan should be considered joint first author.
Abstract: BACKGROUND: Nearly half of adult acute myeloid leukemia (AML) patients were classified into cytogenetic normal acute myeloid leukemia (CN-AML). The expression level of Trophinin associated protein (TROAP) was proven to be associated with the prognosis of several cancers, but it is still unclear in the prognosis of patients with CN-AML. METHODS: We integrated CN-AML patient samples from 4 datasets to analyze the relationship between TROAP expression and the survival of CN-AML. In addition, we investigated 92 AML patients of The Cancer Genome Atlas (TCGA) database to analyze the relationship between TROAP expression and the survival of AML patients received chemotherapy. We investigated the relationship between the expression of TROAP and drug sensitivity in AML cell lines. RESULTS: CN-AML patients with high TROAP expression were related to good event-free survival (EFS) and overall survival (OS). In AML patients received chemotherapy, high TROAP expression was associated with good survival prognosis. Additionally, the expression of TROAP gene in leukemia stem cells (LSC) + group was lower. Among multiple drugs, the lower the expression of TROAP, the lower the IC50. CONCLUSION: TROAP could serve as an independent predictor of CN-AML patients and could act as a potential biomarker for the prognosis of CN-AML. TROAP expression levels were closely correlated with the drug sensitivity of multiple drugs.
